Total Payments
$153,714
2024 Payments
$6,510
Companies
42
Transactions
222
Medicare Patients
11,278
Medicare Billing
$3.2M
Payment Breakdown by Category
Research$129,003 (83.9%)
Other$18,458 (12.0%)
Food & Beverage$4,370 (2.8%)
Consulting$1,750 (1.1%)
Travel$93.20 (0.1%)
Education$39.34 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $129,003 | 68 | 83.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,458 | 39 | 12.0% |
| Food and Beverage | $4,370 | 108 | 2.8% |
| Consulting Fee | $1,750 | 1 | 1.1% |
| Travel and Lodging | $93.20 | 1 | 0.1% |
| Education | $39.34 | 5 | 0.0% |
Payments by Type
Research
$129,003
68 transactions
General
$24,710
154 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Glenmark Pharmaceuticals Inc. | $109,124 | 43 | $0 (2018) |
| Eli Lilly and Company | $15,322 | 4 | $0 (2019) |
| Boehringer Ingelheim International GmbH | $13,846 | 31 | $0 (2024) |
| F. Hoffmann-La Roche AG | $5,534 | 10 | $0 (2020) |
| EMD Serono, Inc. | $1,950 | 15 | $0 (2019) |
| Astellas Pharma Global Development | $1,750 | 1 | $0 (2020) |
| Servier BioInnovation | $1,331 | 3 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $472.35 | 12 | $0 (2023) |
| TESARO, Inc. | $438.53 | 4 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $411.85 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,510 | 26 | Boehringer Ingelheim International GmbH ($4,749) |
| 2023 | $7,191 | 22 | Boehringer Ingelheim International GmbH ($6,341) |
| 2022 | $3,032 | 10 | Boehringer Ingelheim International GmbH ($2,757) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $3,302 | 9 | Astellas Pharma Global Development ($1,750) |
| 2019 | $8,749 | 52 | F. Hoffmann-La Roche AG ($4,258) |
| 2018 | $85,662 | 67 | Glenmark Pharmaceuticals Inc. ($81,349) |
| 2017 | $39,255 | 35 | Glenmark Pharmaceuticals Inc. ($27,775) |
All Payment Transactions
222 individual payment records from CMS Open Payments — Page 3 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/18/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $25.46 | General |
| Category: ONCOLOGY | ||||||
| 06/30/2022 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $692.47 | General |
| 06/30/2022 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $605.91 | General |
| 06/30/2022 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $299.14 | General |
| 06/30/2022 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $299.14 | General |
| 06/30/2022 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $299.14 | General |
| 06/30/2022 | Boehringer Ingelheim International GmbH | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $299.14 | General |
| 04/01/2022 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $139.26 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 12/31/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $872.34 | Research |
| Study: STARTRK 2 RXDX 101 02, ALKA ALKA 372 001 and STARTRK 1 RXDX 101 01 • Category: BioOncology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $266.05 | Research |
| Study: Open Label Dose Escalation and Expansion Study of Entrectinib RXDX 101 in Children, STARTRK 2 RXDX 101 02, ALKA ALKA 372 001 and STARTRK 1 RXDX 101 01 • Category: BioOncology | ||||||
| 10/28/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $115.56 | General |
| Category: Oncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $137.37 | Research |
| Study: A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions, An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult • Category: BioOncology | ||||||
| 09/10/2020 | Clovis Oncology, Inc. | Rubraca (Drug) | Education | In-kind items and services | $3.22 | General |
| Category: Oncology | ||||||
| 07/13/2020 | Astellas Pharma Global Development | PADCEV (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: ONCOLOGY | ||||||
| 03/11/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $13.59 | General |
| Category: ONCOLOGY | ||||||
| 02/20/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $130.46 | General |
| Category: Oncology | ||||||
| 02/05/2020 | PFIZER INC. | IBRANCE (Drug), TALZENNA | Food and Beverage | In-kind items and services | $13.55 | General |
| Category: ONCOLOGY | ||||||
| 12/31/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,234.71 | General |
| Category: None | ||||||
| 12/31/2019 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $366.85 | General |
| Category: None | ||||||
| 11/25/2019 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug), ONIVYDE | Food and Beverage | In-kind items and services | $51.99 | General |
| Category: Oncology/Endocrinology | ||||||
| 11/20/2019 | Novocure Inc. | Oncology (Device) | Food and Beverage | Cash or cash equivalent | $14.05 | General |
| Category: Optune | ||||||
| 11/14/2019 | Novocure Inc. | Oncology (Device) | Food and Beverage | Cash or cash equivalent | $71.50 | General |
| Category: Optune | ||||||
| 11/13/2019 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Education | In-kind items and services | $5.00 | General |
| Category: Oncology | ||||||
| 11/07/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $123.98 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| GSP301-304 | Glenmark Pharmaceuticals Inc. | $27,775 | 10 |
| EFFECTS OF MULTIPLE DOSES OF ABEMACICLIB ON THE PHARMACOKINETICS OF CYTOCHROME P450 -CYP- 1A2, CYP2C9, CYP2D6, AND CYP3A SUBSTRATES -CAFFEINE, WARFARIN, DEXTROMETHORPHAN, AND MIDAZOLAM- IN CANCER PATIENTS | Eli Lilly and Company | $13,769 | 2 |
| MS201943-0029 | EMD Serono, Inc. | $1,666 | 7 |
| A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) | Eli Lilly and Company | $1,467 | 1 |
| S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations | Servier BioInnovation | $1,331 | 3 |
| STARTRK 2 RXDX 101 02, ALKA ALKA 372 001 and STARTRK 1 RXDX 101 01 | F. Hoffmann-La Roche AG | $872.34 | 1 |
| MS201781-0031 | EMD Serono, Inc. | $284.18 | 8 |
| Open Label Dose Escalation and Expansion Study of Entrectinib RXDX 101 in Children, STARTRK 2 RXDX 101 02, ALKA ALKA 372 001 and STARTRK 1 RXDX 101 01 | F. Hoffmann-La Roche AG | $266.05 | 1 |
| A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions, An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult | F. Hoffmann-La Roche AG | $137.37 | 1 |
| A RANDOMIZED PHASE 3 STUDY OF LY2835219 PLUS BEST SUPPORTIVE CARE VERSUS ERLOTINIB PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH STAGE IV NSCLC WITH A DETECTABLE KRAS MUTATION WHO HAVE PROGRESSED AFTER PLATINUM BASED CHEMOTHERAPY | Eli Lilly and Company | $85.80 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 56 | 2,795 | 57,484 | $3.6M | $801,855 |
| 2022 | 53 | 2,666 | 48,493 | $4.0M | $823,339 |
| 2021 | 58 | 3,079 | 85,558 | $4.3M | $882,569 |
| 2020 | 57 | 2,738 | 51,176 | $3.4M | $684,537 |
Total Patients
11,278
Total Services
242,711
Medicare Billing
$3.2M
Procedure Codes
224
All Medicare Procedures & Services
224 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 29 | 11,400 | $1.6M | $488,904 | 31.5% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 15 | 2,300 | $533,570 | $76,704 | 14.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 99 | 264 | $130,944 | $35,946 | 27.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 141 | 342 | $125,856 | $31,282 | 24.9% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 11 | 23 | $110,446 | $27,220 | 24.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 123 | 245 | $173,215 | $24,906 | 14.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 13 | 1,020 | $66,360 | $18,343 | 27.6% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 23 | 5,855 | $117,100 | $13,786 | 11.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 197 | 761 | $48,704 | $7,876 | 16.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 201 | 838 | $16,760 | $7,039 | 42.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 87 | 250 | $39,250 | $5,741 | 14.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 197 | 749 | $26,964 | $5,700 | 21.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 71 | 92 | $23,000 | $5,618 | 24.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 71 | 100 | $31,300 | $5,021 | 16.0% |
| 83735 | Magnesium level | Office | 2023 | 140 | 569 | $16,501 | $3,738 | 22.7% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 174 | 624 | $19,344 | $3,694 | 19.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 34 | 66 | $22,704 | $3,351 | 14.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 17 | 54 | $11,394 | $3,149 | 27.6% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 35 | 176 | $10,560 | $2,979 | 28.2% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 50 | 273 | $15,288 | $2,488 | 16.3% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 76 | 173 | $10,380 | $2,311 | 22.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $9,926 | $2,222 | 22.4% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 12 | 24 | $15,768 | $2,178 | 13.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $6,215 | $1,424 | 22.9% |
| 83550 | Iron binding capacity | Office | 2023 | 75 | 165 | $5,775 | $1,414 | 24.5% |
About Dr. Minal Barve, M.D
Dr. Minal Barve, M.D is a Medical Oncology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245277698.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Minal Barve, M.D has received a total of $153,714 in payments from pharmaceutical and medical device companies, with $6,510 received in 2024. These payments were reported across 222 transactions from 42 companies. The most common payment nature is "" ($129,003).
As a Medicare-enrolled provider, Barve has provided services to 11,278 Medicare beneficiaries, totaling 242,711 services with total Medicare billing of $3.2M. Data is available for 4 years (2020–2023), covering 224 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Dallas, TX
- Active Since 06/01/2006
- Last Updated 08/14/2014
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1245277698
Products in Payments
- Non-Covered Product (Drug) $4,258
- Bavencio (Biological) $1,950
- PADCEV (Drug) $1,750
- ROZLYTREK (Biological) $1,276
- ZEJULA (Drug) $438.53
- XPOVIO (Drug) $385.28
- BRUKINSA (Drug) $291.24
- Imbruvica (Drug) $271.90
- OPDIVO (Biological) $222.97
- Erleada (Drug) $190.45
- Oncology (Device) $156.64
- LYNPARZA (Drug) $148.39
- ERLEADA (Drug) $145.46
- Revlimid (Drug) $143.37
- RYBREVANT (Drug) $129.73
- Yescarta (Drug) $127.80
- IMBRUVICA (Drug) $123.98
- Kyprolis (Biological) $123.70
- GLEEVEC (Drug) $123.53
- TAGRISSO (Drug) $121.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Dallas
Dr. Moshe Levy, Md, MD
Medical Oncology — Payments: $5.0M
Medical Oncology $5.0M
Dr. Eric Nadler, Md, MD
Medical Oncology — Payments: $1.8M
Medical Oncology $1.8M
Dr. Joyce O'shaughnessy, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Dr. Thomas Hutson, Do,Pharmd, DO,PHARMD
Medical Oncology — Payments: $1.3M
Medical Oncology $1.3M
Dr. Tian Zhang, M.d, M.D
Medical Oncology — Payments: $395,066
Medical Oncology $395,066
Dr. Ashwani Agarwal, M.d, M.D
Medical Oncology — Payments: $304,262
Medical Oncology $304,262